枢复宁和胃复安对肺癌化疗引致恶心呕吐疗效分析

EFFECT OF ZOFRAN AND METOCLOPRAMIDE ON CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN LUNG CANCER

自１９９１年１月～９月，选择以顺铂为主的联合化疗方案（ＭＡＰ、ＭＶＰ、ＶＰ１６＋ＤＤＰ等）治疗８０例非小细胞肺癌。分为Ａ、Ｂ二组，即６０ｍｇ／Ｍ２（术后组）和９０ｍｇ／Ｍ２（治疗组）。疗效评定：急性期（ｄ１）枢复宁为９５％，优于胃复安（５７．５％）；延缓期（ｄ２～５）枢复宁为７７．５％，胃复安为８０％。枢复宁副作用是腹胀、便闭、大便干燥和肠蠕动增强，经对症治疗后均好转，未出现椎体外系反应。

Eighty patients with Non-Small cell lung cancer were treated by cisplatin (DDP) combined with scheme of chemotherapy (MAP,MVP,VP16+DDP,et al).A.B groups were divided with DDP 60mg/M2(Post-operated) and 90mg/M2(treated group) respectively. A group: d1 zofran 8mg+NS 50ml q8h or q 12h i.v. for 2 times, 15'each; DX 5mg iv(after zofran first time taken), then chemotherapy; d2～5 zofran 8mg tid po for four days.B group:d1 Metoclopramide 20mg q3h i.m. for four times,DX 5mg i.v.(after Metoclopramide first time taken), Then chemotherapy;d2～5 Metoclopramide 10mg tid po for four days. The evaluation of therapeutic effect: in acnte stage(d1): zofran was 95%(38/40)and excelled the Metoclopramide 57.5%(23/40); in delay stage(d2～5): zofran was 77.5%(31/40) and Metoclopramide 80%(32/40). Side effects of zofran were abdominal distension, constipation, dry stool and increased intestinal peristalsis. Zofran is a strong, highly selective antagonistic drug for 5HT8-acceptor with minimal side effect. It can prevent gastro-intestinal reaction during chemotherapy.